Connor, Clark & Lunn Investment Management (CC&L)’s Fate Therapeutics FATE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-380,862
| Closed | -$3.84M | – | 1310 |
|
|
2022
Q4 | $3.84M | Buy |
380,862
+81,048
| +27% | +$818K | 0.02% | 405 |
|
|
2022
Q3 | $6.72M | Buy |
299,814
+245,639
| +453% | +$5.5M | 0.04% | 265 |
|
|
2022
Q2 | $1.34M | Buy |
54,175
+46,510
| +607% | +$1.15M | 0.01% | 557 |
|
|
2022
Q1 | $297K | Buy |
+7,665
| New | +$297K | ﹤0.01% | 876 |
|
|
2021
Q3 | – | Sell |
-71,184
| Closed | -$6.18M | – | 1104 |
|
|
2021
Q2 | $6.18M | Buy |
71,184
+6,999
| +11% | +$607K | 0.03% | 316 |
|
|
2021
Q1 | $5.29M | Buy |
64,185
+31,410
| +96% | +$2.59M | 0.03% | 343 |
|
|
2020
Q4 | $2.98M | Buy |
32,775
+25,571
| +355% | +$2.32M | 0.02% | 428 |
|
|
2020
Q3 | $288K | Buy |
+7,204
| New | +$288K | ﹤0.01% | 796 |
|
|
2018
Q1 | – | Sell |
-28,900
| Closed | -$177K | – | 742 |
|
|
2017
Q4 | $177K | Sell |
28,900
-36,100
| -56% | -$221K | ﹤0.01% | 729 |
|
|
2017
Q3 | $257K | Buy |
65,000
+1,500
| +2% | +$5.93K | ﹤0.01% | 725 |
|
|
2017
Q2 | $206K | Buy |
63,500
+22,200
| +54% | +$72K | ﹤0.01% | 740 |
|
|
2017
Q1 | $188K | Buy |
+41,300
| New | +$188K | ﹤0.01% | 806 |
|